Literature DB >> 24478274

Long-term outcomes after liver transplantation for deoxyguanosine kinase deficiency: a single-center experience and a review of the literature.

Enke Grabhorn1, Konstantinos Tsiakas, Uta Herden, Lutz Fischer, Peter Freisinger, Thorsten Marquardt, Rainer Ganschow, Andrea Briem-Richter, René Santer.   

Abstract

Deoxyguanosine kinase (DGUOK) deficiency is a well-known cause of hepatocerebral mitochondrial DNA depletion syndromes, which include a broad spectrum of clinical presentations. Affected patients often develop life-threatening liver failure, but the benefits of liver transplantation (LT) are controversial because of the frequently severe neurological involvement due to the underlying mitochondrial disease. We describe the long-term clinical course of 2 patients from our institution and provide an update on their outcomes after LT with this condition. Another 12 pediatric patients were identified through a systematic search of the literature. All 14 reported patients underwent transplantation in infancy despite mild to moderate neurological impairment in some cases. The 2 DGUOK-deficient patients from our center displayed liver failure and mild to moderate neurological involvement. At the time of this writing, they had been followed for 5 and 8 years after LT, both patients were alive, and they had only mild neurological symptoms. Three of the 12 patients identified through the literature review survived for a long time (17, 12, and 23 years); 8 died during early follow-up; and for 1 patient, no follow-up information was available. The 1-year survival rate was 64%; 36% survived for more than 5 years. The long-term survivors had good quality of life. In conclusion, although survival after LT for DGUOK deficiency is lower than survival after LT for other indications, a significant proportion of patients benefit from LT with long-term survival and a stable neurological situation despite initial neurological abnormalities. Nevertheless, a decision to carry out LT for patients with DGUOK deficiency remains difficult because neurological symptoms may occur and worsen after LT despite their absence before transplantation.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24478274     DOI: 10.1002/lt.23830

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

Review 1.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 2.  Therapies for mitochondrial diseases and current clinical trials.

Authors:  Ayman W El-Hattab; Ana Maria Zarante; Mohammed Almannai; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2017-09-18       Impact factor: 4.797

3.  Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.

Authors:  Sílvia Vilarinho; Sinan Sari; Güldal Yilmaz; Amy L Stiegler; Titus J Boggon; Dhanpat Jain; Gulen Akyol; Buket Dalgic; Murat Günel; Richard P Lifton
Journal:  Hepatology       Date:  2016-03-31       Impact factor: 17.425

4.  Inborn errors of purine metabolism: clinical update and therapies.

Authors:  Shanti Balasubramaniam; John A Duley; John Christodoulou
Journal:  J Inherit Metab Dis       Date:  2014-06-28       Impact factor: 4.982

5.  High incidence and variable clinical outcome of cardiac hypertrophy due to ACAD9 mutations in childhood.

Authors:  Marie Collet; Zahra Assouline; Damien Bonnet; Marlène Rio; Franck Iserin; Daniel Sidi; Alice Goldenberg; Caroline Lardennois; Metodi Dimitrov Metodiev; Birgit Haberberger; Tobias Haack; Arnold Munnich; Holger Prokisch; Agnès Rötig
Journal:  Eur J Hum Genet       Date:  2015-12-16       Impact factor: 4.246

6.  Clinical and molecular basis of hepatocerebral mitochondrial DNA depletion syndrome in Japan: evaluation of outcomes after liver transplantation.

Authors:  Masaru Shimura; Naomi Kuranobu; Minako Ogawa-Tominaga; Nana Akiyama; Yohei Sugiyama; Tomohiro Ebihara; Takuya Fushimi; Keiko Ichimoto; Ayako Matsunaga; Tomoko Tsuruoka; Yoshihito Kishita; Shuichiro Umetsu; Ayano Inui; Tomoo Fujisawa; Ken Tanikawa; Reiko Ito; Akinari Fukuda; Jun Murakami; Shunsaku Kaji; Mureo Kasahara; Kazuo Shiraki; Akira Ohtake; Yasushi Okazaki; Kei Murayama
Journal:  Orphanet J Rare Dis       Date:  2020-07-24       Impact factor: 4.123

Review 7.  The Genetics of Inherited Cholestatic Disorders in Neonates and Infants: Evolving Challenges.

Authors:  Rebecca Jeyaraj; Kirsten McKay Bounford; Nicola Ruth; Carla Lloyd; Fiona MacDonald; Christian J Hendriksz; Ulrich Baumann; Paul Gissen; Deirdre Kelly
Journal:  Genes (Basel)       Date:  2021-11-21       Impact factor: 4.096

Review 8.  Clinical trials in mitochondrial disorders, an update.

Authors:  Mohammed Almannai; Ayman W El-Hattab; May Ali; Claudia Soler-Alfonso; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2020-10-06       Impact factor: 4.797

Review 9.  Moving towards clinical trials for mitochondrial diseases.

Authors:  Robert D S Pitceathly; Nandaki Keshavan; Joyeeta Rahman; Shamima Rahman
Journal:  J Inherit Metab Dis       Date:  2020-09-02       Impact factor: 4.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.